Table 2.

Multi-targeted payload in Nanomedicines against cancer MDR at their different stage of preclinical and clinical studies.

Nanomedicines	Multi-targeted payload	Cancer	Preclinical/Clinical	Refs.
Liposomes	Cytarabine + Daunorubicin	Hematologic Cancer	Phase II	[167]
	Irinotecan + Floxuridine	Colorectal Cancer	Phase II	[168]
	siBc1-2-lipoplex+ S- 1(5-FU) pro-drug	Colorectal cancer	Preclinical	[169]
	Irinotecan and Cisplatin	NSCL cancer	Preclinical	[172]
	Doxorubicin+ Msurvivin T34A plasmid	Lung carcinoma	Preclinical	[173]
	Topotecan + Vincristine	Brain cancer	Preclinical	[174]
	Topotecan + Amlodipine	Leukemia	Preclinical	[175]
	Vincristine + Quinacrine	Leukemia	Preclinical	[176]
	6-Mercaptopurine + Daunorubicin	Leukemia	Preclinical	[177]
	Doxorubicin + Verapamil	Leukemia	Preclinical	[178]
	Paclitaxel + Tariquidar	Ovarian cancer	Preclinical	[179]
	siMcll+Suberoylanilidehydroxamic acid	Cervical cancer	Preclinical	[180]
	PD0325901 +siMcll	Cervical cancer	Preclinical	[181]
	Taurocholate+ Suberoylanilidehydroxamic acid	Oral cancer	Preclinical	[182]
	Ceramide+ Sorafenib	Breast Cancer	Preclinical	[183]
	Gemcitabine+Tamoxifen	Breast cancer	Preclinical	[184]
	Combretastatin A-4+ Doxorubicin	Melanoma	Preclinical	[185]
	siB-Raf+ siAkt3	Melanoma	Preclinical	[163]
Dendrimer	Doxorubicin + siRNA	Glioblastoma	Preclinical	[186]
	Antisense-miRNA21 + 5-Fluorouracil	Glioblastoma	Preclinical	[187]
	Paclitaxel + Alendronate	Bone metastases	Preclinical	[188]
	Methotrexate + Trans-retinoic acid	Leukemia	Preclinical	[188]
	Unmethylated CpG-ONTs + Doxorubicin	Prostate	Preclinical	[189]
Magnetic nanopar- ticles	Paclitaxel + Rapamycin	Breast cancer	Preclinical	[190]
Polymeric (PLGA) nanoparticles	Vincristine + Verapamil	Hepatocellular carcinoma	Preclinical	[191]
Polymeric micelle	Doxorubicin+p53 gene	Hepato-carcinoma	Preclinical	[192]